0
TCR2 Therapeutics Inc. Banner Image

TCR2 Therapeutics Inc.

  • Ticker TCRR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
TCR2 Therapeutics Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigensMore (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
TCR2 Therapeutics Inc.

Most Recent Annual Report

TCR2 Therapeutics Inc.
MOST RECENT 2020 Annual Report and Form 10K

Older/Archived Annual Reports